PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?

E-ISSN： 1875-533x|16|8|916-930

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.16, Iss.8, 2009-03, pp. : 916-930

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fragment-Based Drug Discovery: What has it Achieved so Far?

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 16, 2007-08 ,pp. : 1544-1567

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/AKT/mTOR Inhibitors In Ovarian Cancer

Current Medicinal Chemistry, Vol. 17, Iss. 36, 2010-12 ,pp. : 4433-4447

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs

Current Pharmaceutical Design, Vol. 16, Iss. 12, 2010-04 ,pp. : 1410-1416

Bentham Science Publishers

Access to resources Recommend Favorite

Computational Medicinal Chemistry to Design Novel Phosphoinositide 3- Kinase (PI3K) Alpha Inhibitors in View of Cancer

Current Bioactive Compounds, Vol. 10, Iss. 3, 2014-08 ,pp. : 147-157

Bentham Science Publishers

Access to resources Recommend Favorite